Evidence map›Paper›PMID 31979114›Full record

ReviewCancers2020

Molecular Mechanisms of the Efficacy of Cold Atmospheric Pressure Plasma (CAP) in Cancer Treatment.

Marie Luise Semmler, Sander Bekeschus, Mirijam Schäfer, Thoralf Bernhardt, Tobias Fischer, Katharina Witzke, Christian Seebauer, Henrike Rebl, Eberhard Grambow, Brigitte Vollmar and 5 more

Open access · goldAbstract readReview
In one paragraph

Review in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
88citing papers in PubMed, 3 pooled it
15.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

88 citing papers in PubMed, 3 syntheses or guidelines pooled it, 209 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

28 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Marie Luise SemmlerClinic and Polyclinic for Dermatology and Venereology, University Medical Center Rostock, 18057 Rostock, Germany.
Sander BekeschusZIK plasmatis, Leibniz-Institute for Plasma Science and Technology (INP Greifswald), 17489 Greifswald, Germany.
Mirijam SchäferClinic and Polyclinic for Dermatology and Venereology, University Medical Center Rostock, 18057 Rostock, Germany.
Thoralf BernhardtClinic and Polyclinic for Dermatology and Venereology, University Medical Center Rostock, 18057 Rostock, Germany.
Tobias FischerClinic and Polyclinic for Dermatology and Venereology, University Medical Center Rostock, 18057 Rostock, Germany.
Katharina WitzkeOral & Maxillofacial Surgery/Plastic Surgery, University Medicine Greifswald, 17489 Greifswald, Germany.
Christian SeebauerOral & Maxillofacial Surgery/Plastic Surgery, University Medicine Greifswald, 17489 Greifswald, Germany.
Henrike ReblDepartment of Cell Biology, University Medical Center Rostock, 18057 Rostock, Germany.
Eberhard GrambowInstitute for Experimental Surgery, Rostock University Medical Center, 18057 Rostock, Germany.
Brigitte VollmarInstitute for Experimental Surgery, Rostock University Medical Center, 18057 Rostock, Germany.
J Barbara NebeDepartment of Cell Biology, University Medical Center Rostock, 18057 Rostock, Germany.
Hans-Robert MetelmannOral & Maxillofacial Surgery/Plastic Surgery, University Medicine Greifswald, 17489 Greifswald, Germany.
Thomas von WoedtkeZIK plasmatis, Leibniz-Institute for Plasma Science and Technology (INP Greifswald), 17489 Greifswald, Germany.
Steffen EmmertClinic and Polyclinic for Dermatology and Venereology, University Medical Center Rostock, 18057 Rostock, Germany.
Lars BoeckmannClinic and Polyclinic for Dermatology and Venereology, University Medical Center Rostock, 18057 Rostock, Germany.
University of Rostock · DEUniversitätsmedizin Greifswald · DELeibniz Institute for Plasma Science and Technology · DE

Funding

Bundesministerium für Bildung und Forschung 03Z22DN11European Social Fund and Ministry of Education, Science and Culture of Mecklenburg-West Pomerania, Germany ESF/14-BM-A55-0001/18European Social Fund and Ministry of Education, Science and Culture of Mecklenburg-West Pomerania, Germany ESF/14-BM-A55-0002/18European Social Fund and Ministry of Education, Science and Culture of Mecklenburg-West Pomerania, Germany ESF/14-BM-A55-0003/18European Social Fund and Ministry of Education, Science and Culture of Mecklenburg-West Pomerania, Germany ESF/14-BM-A55-0005/18European Social Fund and Ministry of Education, Science and Culture of Mecklenburg-West Pomerania, Germany ESF/14-BM-A55-0006/18
6 · The paper itself

Abstract

Recently, the potential use of cold atmospheric pressure plasma (CAP) in cancer treatment has gained increasing interest. Especially the enhanced selective killing of tumor cells compared to normal cells has prompted researchers to elucidate the molecular mechanisms for the efficacy of CAP in cancer treatment. This review summarizes the current understanding of how CAP triggers intracellular pathways that induce growth inhibition or cell death. We discuss what factors may contribute to the potential selectivity of CAP towards cancer cells compared to their non-malignant counterparts. Furthermore, the potential of CAP to trigger an immune response is briefly discussed. Finally, this overview demonstrates how these concepts bear first fruits in clinical applications applying CAP treatment in head and neck squamous cell cancer as well as actinic keratosis. Although significant progress towards understanding the underlying mechanisms regarding the efficacy of CAP in cancer treatment has been made, much still needs to be done with respect to different treatment conditions and comparison of malignant and non-malignant cells of the same cell type and same donor. Furthermore, clinical pilot studies and the assessment of systemic effects will be of tremendous importance towards bringing this innovative technology into clinical practice.

Indexed as

cold physical plasmaplasma medicinereactive oxygen and nitrogen species

Identifiers

PMID31979114
PMCPMC7072164
OpenAlexW3001687475

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.